Literature DB >> 25072307

Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.

S Fadilah Abdul Wahid1, Nor-Azimah Ismail, Mohd-Razif Mohd-Idris, Fariza Wan Jamaluddin, NorRafeah Tumian, Ernie Yap Sze-Wei, Norasiah Muhammad, Ming Lai Nai.   

Abstract

Currently, the indications to perform reduced-intensity conditioning allogeneic hematopoietic stem cell transplant (RIC-HCT) are based on data derived mainly from large registry and single-centre retrospective studies. Thus, at the present time, there is limited direct evidence supporting the current practice in selecting patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) for RIC versus myeloablative conditioning (MAC) transplants. To determine the relationship between dose intensity of conditioning regimen and survival outcomes after allografting in AML/ALL patients, we performed a meta-analysis of 23 clinical trials reported between 1990 and 2013 involving 15,258 adult patients that compare survival outcomes after RIC-HCT versus MAC-HCT. RIC-HCT resulted in comparable <2-year and 2-6 year overall survival (OS) rates post-transplantation even though the RIC-HCT recipients were older and had more active disease than MAC-HCT recipients. The 2-6 year progression-free survival (PFS), nonrelapse mortality, acute graft-versus-host disease (GvHD) and chronic GvHD rates were reduced after RIC-HCT, but relapse rate was increased. Similar outcomes were observed regardless of disease type and status at transplantation. Odds ratio for all outcomes remained comparable with or without performing separate analyses for the year of HCT and for retrospective versus prospective studies. Among RIC-HCT recipients, survival rates were superior if patients were in CR at transplantation. Significant inter-study heterogeneity for aGvHD data and publication bias for PFS data were observed. This meta-analysis showed no OS benefit of MAC-HCT over RIC-HCT across the entire cohort of patients suggesting that RIC-HCT could be an effective therapeutic option for AML/ALL patients who are ineligible for MAC-HCT and CR status is preferred before RIC-HCT.

Entities:  

Mesh:

Year:  2014        PMID: 25072307      PMCID: PMC4201264          DOI: 10.1089/scd.2014.0123

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  59 in total

Review 1.  Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

Authors:  R Champlin; I Khouri; A Shimoni; J Gajewski; S Kornblau; J Molldrem; N Ueno; S Giralt; P Anderlini
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

2.  T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  J Mattsson; M Uzunel; M Remberger; O Ringdén
Journal:  Transplantation       Date:  2001-02-15       Impact factor: 4.939

3.  Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.

Authors:  R Childs; E Clave; N Contentin; D Jayasekera; N Hensel; S Leitman; E J Read; C Carter; E Bahceci; N S Young; A J Barrett
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

4.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

Authors:  P A McSweeney; D Niederwieser; J A Shizuru; B M Sandmaier; A J Molina; D G Maloney; T R Chauncey; T A Gooley; U Hegenbart; R A Nash; J Radich; J L Wagner; S Minor; F R Appelbaum; W I Bensinger; E Bryant; M E Flowers; G E Georges; F C Grumet; H P Kiem; B Torok-Storb; C Yu; K G Blume; R F Storb
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

5.  Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors.

Authors:  Cristian Carvallo; Nancy Geller; Roger Kurlander; Ramaprasad Srinivasan; Othon Mena; Takehito Igarashi; Linda M Griffith; W Marston Linehan; Richard W Childs
Journal:  Blood       Date:  2003-10-09       Impact factor: 22.113

6.  Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus.

Authors:  A Bacigalupo
Journal:  Bone Marrow Transplant       Date:  2004-04       Impact factor: 5.483

7.  Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.

Authors:  Daniel R Couriel; Rima M Saliba; Sergio Giralt; Issa Khouri; Borje Andersson; Marcos de Lima; Chitra Hosing; Paolo Anderlini; Michelle Donato; Karen Cleary; James Gajewski; Joyce Neumann; Cindy Ippoliti; Gabriela Rondon; Agueda Cohen; Richard Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2004-03       Impact factor: 5.742

8.  Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens.

Authors:  Jane E Parker; Tariq Shafi; Antonio Pagliuca; Aleksandar Mijovic; Stephen Devereux; Mike Potter; H Grant Prentice; Mamta Garg; John A Yin; Jenny Byrne; Nigel H Russell; Ghulam J Mufti
Journal:  Br J Haematol       Date:  2002-10       Impact factor: 6.998

9.  Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.

Authors:  H G Sayer; M Kröger; J Beyer; M Kiehl; S A Klein; K Schaefer-Eckart; R Schwerdtfeger; W Siegert; V Runde; C Theuser; H Martin; J Schetelig; D W Beelen; A Fauser; J Kienast; K Höffken; G Ehninger; M Bornhäuser
Journal:  Bone Marrow Transplant       Date:  2003-06       Impact factor: 5.483

10.  Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.

Authors:  V Bachanova; D I Marks; M-J Zhang; H Wang; M de Lima; M D Aljurf; M Arellano; A S Artz; U Bacher; J-Y Cahn; Y-B Chen; E A Copelan; W R Drobyski; R P Gale; J P Greer; V Gupta; G A Hale; P Kebriaei; H M Lazarus; I D Lewis; V A Lewis; J L Liesveld; M R Litzow; A W Loren; A M Miller; M Norkin; B Oran; J Pidala; J M Rowe; B N Savani; W Saber; R Vij; E K Waller; P H Wiernik; D J Weisdorf
Journal:  Leukemia       Date:  2013-08-30       Impact factor: 11.528

View more
  28 in total

1.  Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis.

Authors:  Zhichao Li; Yinmei Liu; Qing Wang; Linjun Chen; Liyuan Ma; Siguo Hao
Journal:  Acta Haematol       Date:  2019-02-26       Impact factor: 2.195

2.  Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Authors:  Gheath Alatrash; Kelly M Kidwell; Peter F Thall; Antonio Di Stasi; Julianne Chen; Madhushree Zope; Alyssa K Crain; Richard E Champlin; Uday Popat; Elizabeth J Shpall; Roy B Jones; Borje S Andersson
Journal:  Bone Marrow Transplant       Date:  2018-12-10       Impact factor: 5.483

3.  Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.

Authors:  Zheng Zhou; Rajneesh Nath; Jan Cerny; Hai-Lin Wang; Mei-Jie Zhang; Hisham Abdel-Azim; Vaibhav Agrawal; Gulrayz Ahmed; A Samer Al-Homsi; Mahmoud Aljurf; Hassan B Alkhateeb; Amer Assal; Ulrike Bacher; Ashish Bajel; Qaiser Bashir; Minocher Battiwalla; Vijaya Raj Bhatt; Michael Byrne; Jean-Yves Cahn; Mitchell Cairo; Hannah Choe; Edward Copelan; Corey Cutler; Moussab B Damlaj; Zachariah DeFilipp; Marcos De Lima; Miguel Angel Diaz; Nosha Farhadfar; James Foran; César O Freytes; Aaron T Gerds; Usama Gergis; Michael R Grunwald; Zartash Gul; Mehdi Hamadani; Shahrukh Hashmi; Mark Hertzberg; Gerhard C Hildebrandt; Nasheed Hossain; Yoshihiro Inamoto; Luis Isola; Tania Jain; Rammurti T Kamble; Muhammad Waqas Khan; Mohamed A Kharfan-Dabaja; Partow Kebriaei; Natasha Kekre; Nandita Khera; Hillard M Lazarus; Jane L Liesveld; Mark Litzow; Hongtao Liu; David I Marks; Rodrigo Martino; Vikram Mathews; Asmita Mishra; Hemant S Murthy; Arnon Nagler; Ryotaro Nakamura; Sunita Nathan; Taiga Nishihori; Rebecca Olin; Richard F Olsson; Neil Palmisiano; Sagar S Patel; Mrinal M Patnaik; Attaphol Pawarode; Miguel-Angel Perales; Ioannis Politikos; Uday Popat; David Rizzieri; Brenda M Sandmaier; Bipin N Savani; Sachiko Seo; Nirav N Shah; Geoffrey L Uy; David Valcárcel; Leo F Verdonck; Edmund K Waller; Youjin Wang; Daniel Weisdorf; Baldeep Wirk; Eric Wong; Jean A Yared; Wael Saber
Journal:  Blood Adv       Date:  2020-07-14

4.  Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Authors:  Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches
Journal:  Blood Adv       Date:  2019-09-10

5.  Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.

Authors:  R Vrhovac; M Labopin; F Ciceri; J Finke; E Holler; J Tischer; B Lioure; J Gribben; L Kanz; D Blaise; P Dreger; G Held; R Arnold; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

6.  Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.

Authors:  Eric Huselton; Michael Slade; Kathryn M Trinkaus; John F DiPersio; Peter Westervelt; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-24       Impact factor: 5.742

7.  Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.

Authors:  Bipin N Savani; Myriam Labopin; Nicolaus Kröger; Jürgen Finke; Gerhard Ehninger; Dietger Niederwieser; Rainer Schwerdtfeger; Donald Bunjes; Bertram Glass; Gerard Socié; Per Ljungman; Charles Craddock; Frédéric Baron; Fabio Ciceri; Norbert Claude Gorin; Jordi Esteve; Christoph Schmid; Sebastian Giebel; Mohamad Mohty; Arnon Nagler
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

8.  Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.

Authors:  Vishal Dhere; Scott Edelman; Edmund K Waller; Amelia Langston; Michael Graiser; Erin C Connolly; Jeffrey M Switchenko; Natia Esiashvili; Mohammad K Khan
Journal:  Leuk Lymphoma       Date:  2017-08-07

9.  TLI in pediatric patients.

Authors:  A Ocanto; A Escribano; L Glaría; I Rodríguez; C Ferrer; C Huertas; A Pérez; R Morera
Journal:  Clin Transl Oncol       Date:  2019-09-21       Impact factor: 3.405

10.  Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning.

Authors:  Kinjal Sanghavi; Anthony Wiseman; Mark N Kirstein; Qing Cao; Richard Brundage; Kyle Jensen; John Rogosheske; Andy Kurtzweil; Janel Long-Boyle; John Wagner; Erica D Warlick; Claudio G Brunstein; Daniel J Weisdorf; Pamala A Jacobson
Journal:  Transl Res       Date:  2016-03-31       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.